{"id":520380,"date":"2010-04-08T10:09:12","date_gmt":"2010-04-08T14:09:12","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=72476"},"modified":"2010-04-08T10:09:12","modified_gmt":"2010-04-08T14:09:12","slug":"dendreon-hires-roche-sales-boss","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/520380","title":{"rendered":"Dendreon Hires Roche Sales Boss"},"content":{"rendered":"\n
Biotech<\/a>, people<\/a>, cancer<\/a><\/div>\n

\t\tLuke Timmerman wrote:<\/strong><\/p>\n

Dendreon (NASDAQ: DNDN<\/a>), the Seattle-based developer of an immune-stimulating drug for prostate cancer, said today<\/a> it has hired Varun Nanda to be its senior vice president of commercial operations. Nanda was formerly the senior vice president and head of global oncology for Roche, the world’s largest maker of cancer drugs, with hits like rituximab (Rituxan), bevacizumab (Avastin), and trastuzumab (Herceptin). Nanda’s responsibility will be to lead the commercial push for Dendreon’s sipuleucel-T (Provenge), including its sales and marketing. The FDA has a deadline of May 1 to complete its review of Dendreon’s application to market the drug in the U.S.<\/p>\n

Comments<\/a> | Reprints<\/a> | Share:  
\n\"Retweet\"\/<\/a>
\n \"Facebook\"\/<\/a>
\n \"Email\"\/<\/a>
\n \"Share\"\/<\/a>\n<\/div>\n

UNDERWRITERS AND PARTNERS
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t<\/p>\n

\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t\t\t\t

\n

\n\"\"<\/a>
\n<\/p>\n

<\/img><\/a>
\n<\/img><\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Biotech, people, cancer Luke Timmerman wrote: Dendreon (NASDAQ: DNDN), the Seattle-based developer of an immune-stimulating drug for prostate cancer, said today it has hired Varun Nanda to be its senior vice president of commercial operations. Nanda was formerly the senior vice president and head of global oncology for Roche, the world’s largest maker of cancer […]<\/p>\n","protected":false},"author":1192,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-520380","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/520380","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1192"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=520380"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/520380\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=520380"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=520380"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=520380"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}